DK2991989T3 - Imidazo-triazin-derivater som pde10-inhibitorer - Google Patents
Imidazo-triazin-derivater som pde10-inhibitorer Download PDFInfo
- Publication number
- DK2991989T3 DK2991989T3 DK14727054.0T DK14727054T DK2991989T3 DK 2991989 T3 DK2991989 T3 DK 2991989T3 DK 14727054 T DK14727054 T DK 14727054T DK 2991989 T3 DK2991989 T3 DK 2991989T3
- Authority
- DK
- Denmark
- Prior art keywords
- methyl
- compound
- pharmaceutically acceptable
- acceptable salt
- mmol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (26)
1. Forbindelse med formlen:
eller et farmaceutisk acceptabelt salt deraf, hvori: A, sammen med X og carbonatomet, hvortil det er bundet, danner en (C6-Cio)aryl eller en 5- til 10-leddet heteroaryldel, hvori aryl eller heteroaryldelen eventuelt er substitueret med op til 4 substituenter, der hver uafhængigt er udvalgt fra gruppen bestående af C3-C6 cycloalkyl, oxo, eventuelt substitueret CrC6 alkyl, eventuelt substitueret CrC6 alkoxy, hydroxy, cyano, halogen, -NR5R6, -C(0)-NR5R6, -NH-C(0)R5, -C(0)-0R5, -(Ci-C6)alkyl-(C3-C6)cycloalkyl, en 4- til 6-leddet hetero-cyklisk del, phenyl og benzyl; X er repræsenteret ved N eller C; R1 er repræsenteret ved CrC6 alkyl, (C6-Cio)aryl eller en 5- til 6-leddet hete-rocyklisk del, hvori alkyl, aryl eller den heterocykliske del eventuelt kan være substitueret med op til 4 substituenter, der hver uafhængigt er udvalgt fra gruppen bestående af halogen, eventuelt substitueret CrC6 alkyl, eventuelt substitueret C-rC6 alkoxy, hydroxy, cyano, -NR5R6, -C(0)-NR5R6, -NH-C(0)R5 og -C(0)-0R5; R2 og R3 hver uafhængigt er repræsenteret ved hydrogen, eventuelt substitueret CrC6 alkyl, eller eventuelt substitueret CrC6 alkoxy; R4, hvis til stede, eventuelt er repræsenteret ved op til 2 substituenter, der hver uafhængigt er udvalgt fra gruppen bestående af fluor, hydroxy, eventuelt substitueret CrC6 alkyl eller eventuelt substitueret CrC6 alkoxy, og; R5 og R6 hver eventuelt og uafhængigt er repræsenteret ved hydrogen eller CrC6 alkyl.
2. Forbindelse, eller et farmaceutisk acceptabelt salt deraf, ifølge krav 1, hvori R2 er methyl.
3. Forbindelse, eller et farmaceutisk acceptabelt salt deraf, ifølge krav 1 eller 2, hvori R3 er hydrogen.
4. Forbindelse, eller et farmaceutisk acceptabelt salt deraf, ifølge krav 1, 2 eller 3, hvori R1 er repræsenteret ved phenyl, som eventuelt kan være substitueret.
5. Forbindelse, eller et farmaceutisk acceptabelt salt deraf, ifølge krav 4, hvori phenylringen er substitueret med en eller flere substituenter udvalgt fra gruppen bestående af methyl, fluor, methoxy og chlor.
6. Forbindelse, eller et farmaceutisk acceptabelt salt deraf, ifølge krav 1, 2 eller 3, hvori R1 er tetrahydrofuran.
7. Forbindelse, eller et farmaceutisk acceptabelt salt deraf, ifølge krav 6, hvori tetrahydrofuran er usubstitueret.
8. Forbindelse, eller et farmaceutisk acceptabelt salt deraf, ifølge krav 1, 2 eller 3, hvori R1 er tetrahydropyran.
9. Forbindelse, eller et farmaceutisk acceptabelt salt deraf, ifølge krav 8, hvori tetrahydropyran er usubstitueret.
10. Forbindelse, eller et farmaceutisk acceptabelt salt deraf, ifølge et hvilket som helst af kravene 1 til 9, hvori A, sammen med X og carbonatomet, hvortil det er bundet, danner en phenylring.
11. Forbindelse, eller et farmaceutisk acceptabelt salt deraf, ifølge et hvilket som helst af kravene 1 til 9, hvori A, sammen med X og carbonatomet, hvortil det er bundet, danner en heteroaryldel.
12. Forbindelse, eller et farmaceutisk acceptabelt salt deraf, ifølge krav 11, hvori heteroaryldelen indeholder mindst et nitrogenatom.
13. Forbindelse, eller et farmaceutisk acceptabelt salt deraf, ifølge krav 11, hvori heteroaryldelen er udvalgt fra gruppen bestående af pyridin, pyridazin, pyrimidin og pyrazin.
14. Forbindelse, eller et farmaceutisk acceptabelt salt deraf, ifølge krav 11, hvori heteroaryldelen er udvalgt fra gruppen bestående af pyrrol, pyrazol, imidazol, isoxazol, oxazol, isothiazol og thiazol.
15. Forbindelse, eller et farmaceutisk acceptabelt salt deraf, ifølge krav 10, hvori phenylringen er substitueret med en eller flere substituenter udvalgt fra gruppen bestående af methyl, methoxy, chlor, fluor, 2-fluorethoxy, cyano, -C(0)-0FI, -C(0)-NFl2 og trifluormethyl.
16. Forbindelse, eller et farmaceutisk acceptabelt salt deraf, ifølge krav 11, hvori heteroaryl er substitueret med en eller flere substituenter udvalgt fra gruppen bestående af methyl, ethyl, trifluormethyl, difluormethyl, difluor-methoxy, methoxy, isopropyl, cyclopropyl, oxo, hydroxy, ethoxy, phenyl, 2-trifluorethyl, dimethylamino, cyclobutylmethyl, methylamino og cyclopentyl.
17. Forbindelse, eller et farmaceutisk acceptabelt salt deraf, ifølge et hvilket som helst af kravene 1-16, hvori R4 er fraværende.
18. Forbindelse ifølge krav 1 udvalgt fra gruppen bestående af: i) 4-(3-cyclopropyl-6,7-dihydro[1,2]oxazolo[4,3-c]pyridin-5(4/7)-yl)-7-methyl-5-[(3S)-tetrahydrofuran-3-yl]imidazo[5,1 -/][1,2,4]triazin, ii) 4-(2-cyclopropyl-2,4,6,7-tetrahydro-5/-/-pyrazolo[4,3-c]pyridin-5-yl)-7-methyl-5-[(3S)-tetrahydrofuran-3-yl]imidazo[5,1-(|[1,2,4]triazin, iii) 4-(3-cyclopropyl-1 -methyl-1,4,6,7-tetrahydro-5/-/-pyrazolo[4,3-c]pyridin-5-yl)-7-methyl-5-[(3S)-tetrahydrofuran-3-yl]imidazo[5,1-f][1,2,4]triazin, iv) 2-cyclopropyl-6-[5-(2-fluorphenyl)-7-methylimidazo[5,1 -/][1,2,4]triazin-4-yl]-5,6,7,8-tetrahydropyrido[4,3-c/]pyrimidin, v) 4-(2-cyclopropyl-6,7-dihydro[1,3]oxazolo[5,4-c]pyridin-5(4/-/)-yl)-7-methyl-5-[(3S)-tetrahydrofuran-3-yl]imidazo[5,1 -/][1,2,4]triazin, vi) 8-(2-fluorethoxy)-7-methoxy-2-{7-methyl-5-[(3S)-tetrahydrofuran-3-yl]imidazo[5,1 -/][1,2,4]triazin-4-yl}-1,2,3,4-tetrahydroisoquinolin, vii) 5-(2-fluorphenyl)-7-methyl-4-(1 -methyl-1,4,5,7-tetrahydro-6/-/-pyrazolo[3,4-c]pyridin-6-yl)imidazo[5,1 -/][1,2,4]triazin, viii) 7-methyl-4-(1 -methyl-1,4,5,7-tetrahydro-6/-/-pyrazolo[3,4-c]pyridin-6-yl)-5-[(3S)-tetrahydrofuran-3-yl]imidazo[5,1 -fl[1,2,4]triazin, ix) 4-(1 -cyclopropyl-1,4,5,7-tetrahydro-6/-/-pyrazolo[3,4-c]pyridin-6-yl)-7-methyl-5-[(3S)-tetrahydrofuran-3-yl]imidazo[5,1 -/][1,2,4]triazin og; x) 7-methyl-4-(1 -methyl-1,4,5,7-tetrahydro-6/-/-pyrazolo[3,4-c]pyridin-6-yl)-5-[(2fl)-tetrahydrofuran-2-yl]imidazo[5,1 -/][1,2,4]triazin eller et farmaceutisk acceptabelt salt deraf.
19. Forbindelse ifølge krav 1, som er 7-{7-methyl-5-[(3S)-tetrahydrofuran-3-yl]imidazo[5,1 -/][1,2,4]triazin-4-yl}-5,6,7,8-tetrahydro-1,7-naphthyridin eller et farmaceutisk acceptabelt salt deraf.
20. Forbindelse ifølge krav 1, som er 7-methyl-4-(1 -methyl-1,4,5,7- tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-5-[(3S)-tetrahydrofuran-3-yl]imidazo[5,1-/][1,2,4]triazin eller et farmaceutisk acceptabelt salt deraf.
21. Forbindelse ifølge krav 1, som er 7-methyl-4-(1 -methyl-1,4,5,7- tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-5-[(2R)-tetrahydrofuran-2-yl]imidazo[5,1 -/][1,2,4]triazin eller et farmaceutisk acceptabelt salt deraf.
22. Forbindelse ifølge krav 1, som er 8-(2-fluorethoxy)-7-methoxy-2-{7-methyl-5-[(3S)-tetrahydrofuran-3-yl]imidazo[5,1 -/][1,2,4]triazin-4-yl}-1,2,3,4-tetrahydroisoquinolin eller et farmaceutisk acceptabelt salt deraf.
23. Forbindelse ifølge krav 1, som er 4-(2-cyclopropyl-6,7-dihydro[1,3]oxazolo[5,4-c]pyridin-5(4/-/)-yl)-7-methyl-5-[(3S)-tetrahydrofuran-3-yl]imidazo[5,1 -/][1,2,4]triazin eller et farmaceutisk acceptabelt salt deraf.
24. Farmaceutisk sammensætning omfattende en forbindelse eller et farmaceutisk acceptabelt salt ifølge et hvilket som helst af kravene 1-23 sammen med et eller flere farmaceutiske hjælpestoffer.
25. Forbindelse ifølge et hvilket som helst af kravene 1-23 eller et farmaceutisk acceptabelt salt deraf til anvendelse ved behandling af en sygdom udvalgt blandt psykoser, Parkinsons sygdom, demens, Huntingtons sygdom, obsessiv-kompulsiv tilstand, tardiv dyskinesi, chorea, depression, stemnings forstyrrelser, impulsivitet, stofmisbrug, forstyrrelser af opmærksomhed, aktivitet og impulsivitet (ADHD), depression med parkinsonisme-tilstande, personlighedsændringer med caudatus eller putamen-sygdom, demens og mani med caudatus og pallidal-sygdomme og kompulsive symptomer med pallidal-sygdom.
26. Forbindelse til anvendelse ifølge krav 25, hvor sygdommen er Hunting-tons sygdom.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361818650P | 2013-05-02 | 2013-05-02 | |
| PCT/IB2014/060945 WO2014177977A1 (en) | 2013-05-02 | 2014-04-23 | Imidazo-triazine derivatives as pde10 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2991989T3 true DK2991989T3 (da) | 2017-07-31 |
Family
ID=50841902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14727054.0T DK2991989T3 (da) | 2013-05-02 | 2014-04-23 | Imidazo-triazin-derivater som pde10-inhibitorer |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US8933224B2 (da) |
| EP (1) | EP2991989B1 (da) |
| JP (1) | JP6263606B2 (da) |
| KR (1) | KR101770905B1 (da) |
| CN (1) | CN105164134B (da) |
| AP (1) | AP2015008843A0 (da) |
| AR (1) | AR096161A1 (da) |
| AU (1) | AU2014261070A1 (da) |
| BR (1) | BR112015027760A8 (da) |
| CA (1) | CA2910759C (da) |
| CL (1) | CL2015003037A1 (da) |
| CR (1) | CR20150591A (da) |
| CU (1) | CU20150144A7 (da) |
| DK (1) | DK2991989T3 (da) |
| DO (1) | DOP2015000271A (da) |
| EA (1) | EA027936B1 (da) |
| EC (1) | ECSP15050110A (da) |
| ES (1) | ES2637816T3 (da) |
| GE (1) | GEP201706675B (da) |
| HK (1) | HK1213885A1 (da) |
| MA (1) | MA38559B1 (da) |
| MD (1) | MD20150103A2 (da) |
| MX (1) | MX2015015163A (da) |
| NI (1) | NI201500157A (da) |
| NZ (1) | NZ712949A (da) |
| PE (1) | PE20151940A1 (da) |
| PH (1) | PH12015502462A1 (da) |
| SG (1) | SG11201508201VA (da) |
| TN (1) | TN2015000490A1 (da) |
| TW (1) | TWI508966B (da) |
| UA (1) | UA111696C2 (da) |
| UY (1) | UY35547A (da) |
| WO (1) | WO2014177977A1 (da) |
| ZA (1) | ZA201508968B (da) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201508201VA (en) * | 2013-05-02 | 2015-11-27 | Pfizer | Imidazo-triazine derivatives as pde10 inhibitors |
| KR102411532B1 (ko) | 2016-09-09 | 2022-06-22 | 노파르티스 아게 | 엔도솜 톨-유사 수용체의 억제제로서의 화합물 및 조성물 |
| AU2020370958A1 (en) * | 2019-10-21 | 2022-06-09 | Sk Biopharmaceuticals Co., Ltd. | Use of imidazopyrimidine or imidazotriazine compounds for prevention, alleviation, or treatment of cognitive disorders, or for improving cognitive function |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010007867A1 (en) | 1999-12-13 | 2001-07-12 | Yuhpyng L. Chen | Substituted 6,5-hetero-bicyclic derivatives |
| DE10130167A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Imidazotriazine |
| US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| DE10230604A1 (de) | 2002-07-08 | 2004-01-29 | Bayer Ag | Heterocyclisch substituierte Imidazotriazine |
| WO2005012485A2 (en) | 2003-07-31 | 2005-02-10 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
| JP4559749B2 (ja) * | 2004-02-16 | 2010-10-13 | あすか製薬株式会社 | ピペラジニルピリジン誘導体 |
| EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| US20070167426A1 (en) | 2004-06-02 | 2007-07-19 | Schering Corporation | Compounds for the treatment of inflammatory disorders and microbial diseases |
| TW200716102A (en) | 2005-06-01 | 2007-05-01 | Wyeth Corp | Bicyclic 6-alkylidene-penems as class-D β -lactamases inhibitors |
| US20080051419A1 (en) | 2006-07-26 | 2008-02-28 | Pfizer Inc. | Amine derivatives useful as anticancer agents |
| EP2067769A1 (en) | 2006-09-26 | 2009-06-10 | Kaneka Corporation | Process for producing optically active beta-hydroxy-alpha-aminocarboxylic acid ester |
| WO2008057402A2 (en) | 2006-11-02 | 2008-05-15 | Cytovia, Inc. | N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof |
| EP2203171A2 (en) | 2007-08-21 | 2010-07-07 | Merck Sharp & Dohme Corp. | Cb2 receptor ligands for the treatment of pain |
| DE102007059723A1 (de) | 2007-12-12 | 2009-06-18 | Siemens Medical Instruments Pte. Ltd. | Hörvorrichtung mit Batterieklappenmodul |
| PE20091057A1 (es) | 2007-12-19 | 2009-07-20 | Lilly Co Eli | Antagonistas del receptor mineralcorticoide y metodos de uso |
| WO2009117157A1 (en) | 2008-03-20 | 2009-09-24 | Amgen Inc. | Aurora kinase modulators and method of use |
| JP5641664B2 (ja) * | 2009-10-30 | 2014-12-17 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ | イミダゾ［１，２−ｂ］ピリダジン誘導体およびＰＤＥ１０阻害剤としてのそれらの使用 |
| WO2011089400A1 (en) | 2010-01-22 | 2011-07-28 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Inhibitors of pi3 kinase |
| AR080754A1 (es) * | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| TW201200518A (en) | 2010-03-10 | 2012-01-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| US20130131057A1 (en) | 2010-05-13 | 2013-05-23 | Centro Nacional De Investigaciones Oncologicas (Cnio | New bicyclic compounds as pi3-k and mtor inhibitors |
| CN102971323A (zh) | 2010-05-28 | 2013-03-13 | 拜奥克里斯特制药公司 | 作为janus激酶抑制剂的杂环化合物 |
| JP2013532149A (ja) | 2010-06-17 | 2013-08-15 | ノバルティス アーゲー | ピペリジニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体 |
| EP2681218A1 (en) * | 2011-02-23 | 2014-01-08 | Pfizer Inc | IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
| SG11201508201VA (en) * | 2013-05-02 | 2015-11-27 | Pfizer | Imidazo-triazine derivatives as pde10 inhibitors |
-
2014
- 2014-04-23 SG SG11201508201VA patent/SG11201508201VA/en unknown
- 2014-04-23 GE GEAP201413979A patent/GEP201706675B/en unknown
- 2014-04-23 DK DK14727054.0T patent/DK2991989T3/da active
- 2014-04-23 UA UAA201510060A patent/UA111696C2/uk unknown
- 2014-04-23 ES ES14727054.0T patent/ES2637816T3/es active Active
- 2014-04-23 PE PE2015002303A patent/PE20151940A1/es not_active Application Discontinuation
- 2014-04-23 AP AP2015008843A patent/AP2015008843A0/xx unknown
- 2014-04-23 CN CN201480024798.1A patent/CN105164134B/zh not_active Expired - Fee Related
- 2014-04-23 MD MDA20150103A patent/MD20150103A2/ro not_active Application Discontinuation
- 2014-04-23 KR KR1020157034216A patent/KR101770905B1/ko active IP Right Grant
- 2014-04-23 TN TN2015000490A patent/TN2015000490A1/fr unknown
- 2014-04-23 BR BR112015027760A patent/BR112015027760A8/pt not_active Application Discontinuation
- 2014-04-23 MX MX2015015163A patent/MX2015015163A/es unknown
- 2014-04-23 NZ NZ712949A patent/NZ712949A/en not_active IP Right Cessation
- 2014-04-23 EP EP14727054.0A patent/EP2991989B1/en active Active
- 2014-04-23 AU AU2014261070A patent/AU2014261070A1/en not_active Abandoned
- 2014-04-23 EA EA201591819A patent/EA027936B1/ru not_active IP Right Cessation
- 2014-04-23 CA CA2910759A patent/CA2910759C/en not_active Expired - Fee Related
- 2014-04-23 JP JP2016511150A patent/JP6263606B2/ja not_active Expired - Fee Related
- 2014-04-23 MA MA38559A patent/MA38559B1/fr unknown
- 2014-04-23 WO PCT/IB2014/060945 patent/WO2014177977A1/en active Application Filing
- 2014-04-29 TW TW103115365A patent/TWI508966B/zh not_active IP Right Cessation
- 2014-04-30 UY UY0001035547A patent/UY35547A/es not_active Application Discontinuation
- 2014-04-30 AR ARP140101792A patent/AR096161A1/es unknown
- 2014-04-30 US US14/265,458 patent/US8933224B2/en not_active Expired - Fee Related
- 2014-11-21 US US14/549,871 patent/US9145427B2/en not_active Expired - Fee Related
-
2015
- 2015-08-19 US US14/829,842 patent/US9296761B2/en not_active Expired - Fee Related
- 2015-10-13 CL CL2015003037A patent/CL2015003037A1/es unknown
- 2015-10-19 CU CUP2015000144A patent/CU20150144A7/es unknown
- 2015-10-23 PH PH12015502462A patent/PH12015502462A1/en unknown
- 2015-10-27 CR CR20150591A patent/CR20150591A/es unknown
- 2015-10-30 NI NI201500157A patent/NI201500157A/es unknown
- 2015-11-02 DO DO2015000271A patent/DOP2015000271A/es unknown
- 2015-11-30 EC ECIEPI201550110A patent/ECSP15050110A/es unknown
- 2015-12-01 ZA ZA2015/08968A patent/ZA201508968B/en unknown
-
2016
- 2016-02-18 HK HK16101771.5A patent/HK1213885A1/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102507287B1 (ko) | Ｐｉ３ｋ 억제제로서 헤테로시클릴아민 | |
| US8962596B2 (en) | 5,7-substituted-imidazo[1,2-C]pyrimidines as inhibitors of JAK kinases | |
| US7176203B2 (en) | Imidazo-triazine derivatives as ligands for gaba receptors | |
| AU2016322813A1 (en) | Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors | |
| US20040092533A1 (en) | Imidazo-pyrimidine derivatives as ligands for gaba receptors | |
| TW201326173A (zh) | ５，７－經取代之－咪唑并［１，２－ｃ］嘧啶 | |
| ES2967489T3 (es) | Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1 | |
| TW201300391A (zh) | 作為ｐｄｅ１０ａ酵素抑制劑的咪唑衍生物 | |
| AU2020410470B2 (en) | Triazolopyridazine derivative, preparation method therefor, pharmaceutical composition thereof, and use thereof | |
| US9296761B2 (en) | Triazine derivatives | |
| WO2020163193A1 (en) | Bicyclic ether o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| OA17580A (en) | Imidazo-Triazine derivatives as PDE 10 inhibitors. | |
| AU2015201991A1 (en) | 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of JAK kinases | |
| WO2015113980A1 (en) | (hetero)aryl imidazoles/pyrazoles for treatment of neurological disorders |